A fundamental question is whether thalidomide (1) is stereospecifically teratogenic. The revival of 1 in the clinical field in the 21st century has re-activated an investigation of the molecular mechanism of the teratogenicity of 1. [1][2][3][4][5][6][7][8] Thalidomide (1) was popular especially for pregnant women as an effective antiemetic for morning sickness in the 1950-60s. The teratogenic side effects, leading to birth defects such as limb reduction, produced one of the most notorious medical disasters of modern medical history, and 1 was consequently withdrawn from the market in 1962. Thalidomide (1) possesses an asymmetric center in the glutarimide ring. Since 1 was marketed as a racemate, it was conceivable that sedative effects of 1 might be associated with one enantiomer and the unexpected teratogenic side effects might be ascribed to the other enantiomer. Twenty years after the thalidomide disaster, only (S)-thalidomide (1) was proved to be teratogenic.9) It was then concluded that the disaster could have been avoided if only the (R)-isomer of 1 had been marketed. However, it is presently unclear whether any of the actions of racemic 1 can be separated out using a pure enantiomer. According to the reports, considerable chiral inversion took place after incubation of enantiomerically pure 1. The strongly acidic hydrogen atom at the asymmetric center of 1 rapidly epimerizes under physiological conditions, rendering bioassay of the enantiomers difficult.10-12) Therefore, elucidation of the difference of biological activities between thalidomide enantiomers previously reported is said to be difficult. Therefore, the development of non-racemizable, chiral analogues of thalidomide has attracted much attention.13-16) 3Ј-Fluorothalidimide (2) was developed for this purpose several years ago by a member of our group and by others.17,18) Although the fluorine atom at the asymmetric center of 2 effectively obstructs racemization, the fluorine atom also introduces substantial electronic alterations into the molecule due to its highest electron negativity of 4.0, alterations that could be expected to significantly modulate biological activity. 19) Incidentally, deuterated drugs have been noted as a new strategy for drug discovery. [20][21][22][23][24][25] They have basically the same properties as hydrogenated compounds, but are resistant to metabolism due to the higher stability of the carbon-deuterium (C-D) bond than that of the carbon-hydrogen (C-H) bond. As a result of our research designed to produce an analogue of thalidomide that is resistant to racemization and is also a close structural mimic, [26][27][28][29] we describe herein the design and synthesis of 3Ј-deuteriothalidomide (3), the most closed isostere of thalidomide (Fig. 1). Deuterium at the 3Ј-position of 3 is expected to effectively block the racemization of thalidomide due to its isotopic effect without major alterations of biological activities.
Results and DiscussionOptically pure 3Ј-deuteriothalidomide (3) was synthesized in four steps from ...